Diffuse Large B-Cell Lymphoma Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.
Featured
Mehdi Hamadani, MD, discusses an analysis evaluating the role of autologous transplant in relapsed DLBCL with newer therapies, specifically CAR T-cells.
View More
Dr Neelapu talks about early findings from the ALPHA study which suggest that ALLO-501 and ALLO-647 are safe and may be effective in LBCL.
View More
Nilanjan Ghosh, MD, reviews results from a pilot study of lisocabtagene maraleucel for the treatment of relapsed large cell lymphomas.
View More
Dr Torka talks about the outcomes of patients with limited-stage, aggressive large B-cell lymphoma and high-risk cytogenetics.
View More
Sarah Rutherford, MD, discusses how postinduction bone marrow biopsy histology minimally affects radiographically-defined responses in patients with FL and DLBCL.
View More
Sarah Rutherford, MD, discusses the results from a phase 1 study, which evaluated the combination of venetoclax and DA-EPOCH-R for aggressive B-cell lymphomas.
View More
Wendy Osborne, MBBS (Hons), MRCP, FRCPath, discusses results from the phase 1 Alexander study, which evaluated AUTO3 plus pembrolizumab in relapsed/refractory DLBCL.
View More
John Kuruvilla, MD, FRCPC, discusses the results from the phase 3 KEYNOTE‑204 trial, which compared pembrolizumab against brentuximab vedotin in relapsed/refractory classical Hodgkin lymphoma.
View More
Charles Herbaux, MD, MSc, discusses results from the phase 2 GATA study, which evaluated the efficacy and safety of obinutuzumab plus atezolizumab and venetoclax for relapsed/refractory DLBCL.
View More
Stay in the know.
OncNet Newsletter